{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:52Z","timestamp":1772165752445,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pooyesh Darou"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cancer patients in a non-inferiority clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized clinical trial, 80 patients were recruited and allocated randomly to two equal arms. In one group, a single subcutaneous dose of PDL was injected the day after receiving the chemotherapy regimen in each cycle. The second arm received a subcutaneous injection of PDG for six consecutive days in each cycle of treatment. The side effects of GCF treatment and its effect on blood parameters were compared in each cycle and during eight cycles of chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Hematologic parameters showed no significant differences in any of the treatment courses between the two study groups. The comparison of WBC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.527), Hgb (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.075), Platelet (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.819), Neutrophil (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.575), Lymphocyte (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009705) and ANC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.675) changes during the eight courses of treatment also revealed no statistically significant difference between the two study groups. Side effects including headache, injection site reaction and muscle pain had a lower frequency in patients receiving PDL drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of chemotherapy-induced neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.irct.ir\/search\/result?query=IRCT20190504043465N1\">IRCT20190504043465N1<\/jats:ext-link>\n                      , May 2019.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08197-6","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T09:09:19Z","timestamp":1619168959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparing the efficacy and side-effects of PDLASTA\u00ae (Pegfilgrastim) with PDGRASTIM\u00ae (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Safa","family":"Najafi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahid","family":"Kaveh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6938-467X","authenticated-orcid":false,"given":"Shahpar","family":"Haghighat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"8197_CR1","volume-title":"Granulocyte colony-stimulating factor: key (f) actor or innocent bystander in the development of secondary myeloid malignancy? Oxford University Press","author":"IP Touw","year":"2007","unstructured":"Touw IP, Bontenbal M. Granulocyte colony-stimulating factor: key (f) actor or innocent bystander in the development of secondary myeloid malignancy? Oxford University Press; 2007."},{"issue":"2","key":"8197_CR2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood.V97.2.376","volume":"97","author":"S Calderwood","year":"2001","unstructured":"Calderwood S, Kilpatrick L, Douglas SD, Freedman M, Smith-Whitley K, Rolland M, et al. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and\/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood. 2001;97(2):376\u201382.","journal-title":"Blood"},{"issue":"1","key":"8197_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"M Green","year":"2003","unstructured":"Green M, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29\u201335. https:\/\/doi.org\/10.1093\/annonc\/mdg019.","journal-title":"Ann Oncol"},{"issue":"4","key":"8197_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/s-2000-9668","volume":"212","author":"C Zeidler","year":"2000","unstructured":"Zeidler C, Schwinzer B, Welte K. Severe congenital neutropenia: trends in diagnosis and therapy. Klinische Padiatrie. 2000;212(4):145\u201352. https:\/\/doi.org\/10.1055\/s-2000-9668.","journal-title":"Klinische Padiatrie"},{"issue":"3","key":"8197_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00062752-199704030-00011","volume":"4","author":"MH Freedman","year":"1997","unstructured":"Freedman MH. Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia. Curr Opin Hematol. 1997;4(3):217\u201324. https:\/\/doi.org\/10.1097\/00062752-199704030-00011.","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"8197_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0022-3476(96)70120-8","volume":"129","author":"JC Bernini","year":"1996","unstructured":"Bernini JC, Wooley R, Buchanan GR. Low-dose recombinant human granulocyte colony-stimulating factor therapy in children with symptomatic chronic idiopathic neutropenia. J Pediatr. 1996;129(4):551\u20138. https:\/\/doi.org\/10.1016\/S0022-3476(96)70120-8.","journal-title":"J Pediatr"},{"issue":"4","key":"8197_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1365-2141.1994.tb05110.x","volume":"88","author":"MA Bonilla","year":"1994","unstructured":"Bonilla MA, Dale D, Zeidler C, Last L, Reiter A, Ruggeiro M, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol. 1994;88(4):723\u201330. https:\/\/doi.org\/10.1111\/j.1365-2141.1994.tb05110.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"8197_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/stem.5530130201","volume":"13","author":"DC Dale","year":"1995","unstructured":"Dale DC. Hematopoietic growth factors for the treatment of severe chronic neutropenia. Stem Cells. 1995;13(2):94\u2013100. https:\/\/doi.org\/10.1002\/stem.5530130201.","journal-title":"Stem Cells"},{"issue":"1","key":"8197_CR9","first-page":"45","volume":"90","author":"J Donadieu","year":"2005","unstructured":"Donadieu J, Leblanc T, Meunier BB, Barkaoui M, Fenneteau O, Bertrand Y, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica. 2005;90(1):45\u201353.","journal-title":"Haematologica"},{"issue":"2","key":"8197_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1440-1754.2001.00607.x","volume":"37","author":"T Leung","year":"2001","unstructured":"Leung T, Li C, Kwok K, Chik K, Shing M, Yuen P. Severe chronic neutropenia in Chinese children in Hong Kong. J Paediatr Child Health. 2001;37(2):137\u201341. https:\/\/doi.org\/10.1046\/j.1440-1754.2001.00607.x.","journal-title":"J Paediatr Child Health"},{"key":"8197_CR11","volume-title":"Increased serum levels of granulocyte colony-stimulating factor in patients with severe congenital neutropenia","author":"K Mempel","year":"1991","unstructured":"Mempel K, Pietsch T, Menzel T, Zeidler C, Welte K. Increased serum levels of granulocyte colony-stimulating factor in patients with severe congenital neutropenia; 1991."},{"issue":"4","key":"8197_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s002770050156","volume":"72","author":"K Welte","year":"1996","unstructured":"Welte K, Dale D. Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol. 1996;72(4):158\u201365. https:\/\/doi.org\/10.1007\/s002770050156.","journal-title":"Ann Hematol"},{"issue":"11","key":"8197_CR13","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1182\/blood-2006-09-045427","volume":"109","author":"M Donini","year":"2007","unstructured":"Donini M, Fontana S, Savoldi G, Vermi W, Tassone L, Gentili F, et al. G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms. Blood. 2007;109(11):4716\u201323. https:\/\/doi.org\/10.1182\/blood-2006-09-045427.","journal-title":"Blood"},{"key":"8197_CR14","first-page":"134","volume-title":"Seminars in hematology","author":"TE Cottle","year":"2002","unstructured":"Cottle TE, Fier CJ, Donadieu J, Kinsey SE. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. In: Seminars in hematology, vol. 2. Elsevier; 2002. p. 134\u201340."},{"issue":"12","key":"8197_CR15","first-page":"397","volume":"121","author":"C Ruef","year":"1991","unstructured":"Ruef C, Coleman D. GM-CSF and G-CSF: cytokines in clinical application. Schweizerische Medizinische Wochenschrift. 1991;121(12):397\u2013412.","journal-title":"Schweizerische Medizinische Wochenschrift"},{"key":"8197_CR16","volume-title":"Granulocyte colony-stimulating factor, congenital neutropenia, and acute myeloid leukemia. Mass Medical Soc","author":"E Naparstek","year":"1995","unstructured":"Naparstek E. Granulocyte colony-stimulating factor, congenital neutropenia, and acute myeloid leukemia. Mass Medical Soc; 1995."},{"key":"8197_CR17","doi-asserted-by":"publisher","DOI":"10.4236\/jct.2012.32021","volume-title":"The use of Neupogen (filgrastim) or Neulasta (pegfilgrastim) during pregnancy when chemotherapy is indicated for maternal cancer treatment","author":"E Cardonick","year":"2012","unstructured":"Cardonick E, Irfan F, Torres N. The use of Neupogen (filgrastim) or Neulasta (pegfilgrastim) during pregnancy when chemotherapy is indicated for maternal cancer treatment; 2012."},{"key":"8197_CR18","volume-title":"A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia","author":"DC Dale","year":"1993","unstructured":"Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia; 1993."},{"issue":"4","key":"8197_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1055\/s-2001-16853","volume":"213","author":"T Lehrnbecher","year":"2001","unstructured":"Lehrnbecher T. Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia. Klinische Padiatrie. 2001;213(4):212\u201338. https:\/\/doi.org\/10.1055\/s-2001-16853.","journal-title":"Klinische Padiatrie"},{"issue":"1","key":"8197_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1046\/j.1365-2141.2000.02072-1.x","volume":"110","author":"M Sotomatsu","year":"2000","unstructured":"Sotomatsu M, Kanazawa T, Ogawa C, Watanabe T, Morikawa A. Complication of rapidly progressive glomerulonephritis in severe congenital neutropenia treated with long-term granulocyte colony-stimulating factor (filgrastim). Br J Haematol. 2000;110(1):234\u20135. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.02072-1.x.","journal-title":"Br J Haematol"},{"issue":"1","key":"8197_CR21","first-page":"2","volume":"90","author":"C Niemeyer","year":"2005","unstructured":"Niemeyer C, Kratz C. Is granulocyte colony-stimulating factor therapy a risk factor for myelodysplasia\/leukemia in patients with congenital neutropenia? Haematologica. 2005;90(1):2\u20133.","journal-title":"Haematologica"},{"issue":"4","key":"8197_CR22","first-page":"1195","volume":"95","author":"C Zeidler","year":"2000","unstructured":"Zeidler C, Welte K, Barak Y, Barriga F, Bolyard A, Boxer L, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood. 2000;95(4):1195\u20138.","journal-title":"Blood"},{"issue":"6","key":"8197_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/00130832-200412000-00007","volume":"4","author":"R Badolato","year":"2004","unstructured":"Badolato R, Fontana S, Notarangelo LD, Savoldi G. Congenital neutropenia: advances in diagnosis and treatment. Curr Opin Allergy Clin Immunol. 2004;4(6):513\u201321. https:\/\/doi.org\/10.1097\/00130832-200412000-00007.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"8197_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"F Holmes","year":"2002","unstructured":"Holmes F, Jones S, O\u2019shaughnessy J, Vukelja S, George T, Savin M, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13(6):903\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdf130.","journal-title":"Ann Oncol"},{"issue":"3","key":"8197_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"F Holmes","year":"2002","unstructured":"Holmes F, O\u2019shaughnessy J, Vukelja S, Jones S, Shogan J, Savin M, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol. 2002;20(3):727\u201331. https:\/\/doi.org\/10.1200\/JCO.2002.20.3.727.","journal-title":"J Clin Oncol"},{"issue":"5","key":"8197_CR26","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1110\/ps.052004006","volume":"15","author":"RS Rajan","year":"2006","unstructured":"Rajan RS, Li T, Aras M, Sloey C, Sutherland W, Arai H, et al. Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci. 2006;15(5):1063\u201375. https:\/\/doi.org\/10.1110\/ps.052004006.","journal-title":"Protein Sci"},{"issue":"3","key":"8197_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2010.04.021","volume":"145","author":"Y-J Wang","year":"2010","unstructured":"Wang Y-J, Hao S-J, Liu Y-D, Hu T, Zhang G-F, Zhang X, et al. PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin. J Control Release. 2010;145(3):306\u201313. https:\/\/doi.org\/10.1016\/j.jconrel.2010.04.021.","journal-title":"J Control Release"},{"issue":"12","key":"8197_CR28","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.procbio.2007.09.005","volume":"42","author":"X-Q Li","year":"2007","unstructured":"Li X-Q, Lei J-D, Su Z-G, Ma G-H. Comparison of bioactivities of monopegylated rhG-CSF with branched and linear mPEG. Process Biochem. 2007;42(12):1625\u201331. https:\/\/doi.org\/10.1016\/j.procbio.2007.09.005.","journal-title":"Process Biochem"},{"issue":"1\u20132","key":"8197_CR29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpharm.2009.11.034","volume":"387","author":"FD da Silva","year":"2010","unstructured":"da Silva FD, Spencer PJ, Vass\u00e3o RC, Abrah\u00e3o-Neto J. Biochemical and biopharmaceutical properties of PEGylated uricase. Int J Pharm. 2010;387(1\u20132):215\u201322.","journal-title":"Int J Pharm"},{"issue":"8","key":"8197_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1461-5347(98)00086-8","volume":"1","author":"P Bailon","year":"1998","unstructured":"Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharmaceutical Sci Technol Today. 1998;1(8):352\u20136. https:\/\/doi.org\/10.1016\/S1461-5347(98)00086-8.","journal-title":"Pharmaceutical Sci Technol Today"},{"key":"8197_CR31","volume-title":"Evaluation of pegylation reaction and purification of monopegylated recombinant human granulocyte colony stimulating factor","author":"K Tiwari","year":"2011","unstructured":"Tiwari K, Kattavarapu K, Shebannavar SN, Pokalwar S, Mishra MK, Chauhan UKS. Evaluation of pegylation reaction and purification of monopegylated recombinant human granulocyte colony stimulating factor; 2011."},{"issue":"12","key":"8197_CR32","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1182\/blood-2007-08-106807","volume":"110","author":"LMR Choi","year":"2007","unstructured":"Choi LMR, Guelcher C, Guerrera MF. Novel treatment for severe congenital neutropenia with pegfilgrastim. Blood. 2007;110(12):4134.","journal-title":"Blood"},{"issue":"1","key":"8197_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-0609.2008.01145.x","volume":"82","author":"PM L\u00e4hteenm\u00e4ki","year":"2009","unstructured":"L\u00e4hteenm\u00e4ki PM, Jahnukainen K, Pelliniemi TT, Kainulainen L, Salmi TT. Severe congenital neutropenia and pegfilgrastim. Eur J Haematol. 2009;82(1):75\u20136. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01145.x.","journal-title":"Eur J Haematol"},{"issue":"3","key":"8197_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3324\/haematol.12081","volume":"93","author":"I Bruns","year":"2008","unstructured":"Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S, et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica. 2008;93(3):347\u201355.","journal-title":"Haematologica"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08197-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08197-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08197-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T09:12:01Z","timestamp":1619169121000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08197-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8197"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08197-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-78768\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Ethics Committee of the Breast Cancer Research Center and registered with the code: IR.ACECR.IBCRC.REC.1395.19. All the participants signed written informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"454"}}